The Audited Finanacial Results (Standalone and Consolidated ) of the Company for Last Quarter and Year Ended March 31, 2025 and Audited Annual Accounts of the Company for the quarter and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Note: The filing headline mentions Supha Pharmachem Ltd, but the document provided is for Remedium Lifecare Limited. The company reported audited standalone and consolidated results for FY25, audited by Taori Sandeep & Associates with an unqualified opinion. On a standalone basis, revenue from operations crashed sharply from Rs 4,07,706.07 lakh in FY24 to Rs 73,345.78 lakh in FY25 (an ~82% fall), while standalone profit after tax dropped from Rs 3,273.02 lakh to Rs 153.20 lakh (an ~95% fall). Q4 FY25 standalone turned into a loss of Rs 264.34 lakh. Consolidated revenue for FY25 stood at Rs 40,525.11 lakh with a PAT of Rs 212.94 lakh, reflecting a newly added subsidiary, Remlife Global PTE LTD (Singapore), which began operations only in Q4 FY25. Total expenses stayed high at Rs 41,166.93 lakh (consolidated), leaving thin margins.
The steep revenue and profit slide year-on-year, combined with a sharp rise in borrowings (from Rs 32,098 lakh to Rs 1,14,139 lakh at the standalone level), a deeply negative operating cash flow, and a Q4 loss, raises red flags for shareholders. Investors should note the mismatch between the BSE headline (Supha Pharmachem) and the actual filing company (Remedium Lifecare) before acting.